Video: Chris Viehbacher Interviewed At BioPharm America
This article was originally published in Scrip
Executive Summary
Since his departure from Sanofi, Christopher Viehbacher has taken on a significant role in venture capital. At the BioPharm America 2015 conference in Boston, Massachusetts, he spoke about his company's business model and goals, as well as the trend of pharma execs moving into smaller companies.
You may also be interested in...
Deal Watch: BMS To Tap Early-Stage Breakthroughs In Partnership With BioMotiv
Bristol-Myers Squibb will partner with the biotech accelerator to fund and launch biotechs, with the pharma getting an option to buy. Novartis signs another agreement with IFM months after buying its IFM Tre affiliate.
Panel: Investing Beyond IO Set To Heat Up
Panelists at the World Medical Innovation Forum discussed the new opportunities they are looking at and where the money will be going in the future.
Asia Deal Watch: BIOCAD, Shanghai Pharma Agree On Pair Of Russian/Chinese Joint Ventures
The JVs will develop and commercialize therapeutics for multiple cancer types and autoimmune disorders in China. Novocure partners its Tumor Treating Fields technology with Zai Lab, while Fate and ONO will collaborate on off-the-shelf CAR-T therapies.